View : 108 Download: 0
Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial
- Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial
- Kim, Joon Sung; Kim, Byung-Wook; Hong, Su Jin; Kim, Jin Il; Shim, Ki-Nam; Kim, Jie-Hyun; Baik, Gwang Ho; Kim, Sang Wook; Song, Hyun Joo; Kim, Ji Hyun
- Ewha Authors
- SCOPUS Author ID
- Issue Date
- Journal Title
- GUT AND LIVER
- 1976-2283; 2005-1212
- vol. 10, no. 4, pp. 556 - 561
- Helicobacter pylori; Drug resistance; Disease eradication
- EDITORIAL OFFICE GUT & LIVER
- SCIE; SCOPUS; KCI
- Background/Aims: Eradication of Helicobacter pylori infection with standard triple therapy (TT) has declined primarily because of increased antibiotic resistance. Sequential therapy (ST) has been suggested as an alternative to TT for the first-line treatment of H. pylori. The purpose of this study was to compare the efficacy of ST with TT. Methods: This was a multicenter, randomized open-label trial performed at nine centers in Korea. Patients with H. pylori infection were randomly assigned to receive either 7 day TT or 10 day ST. Eradication rates, drug compliance, and adverse events were Compared among the two regimens. Results: A total of 601 patients were enrolled between March 2011 and September 2014. The intention-to-treat eradication rates were 70.8% for TT and 82.4% for ST (p=0.001). The corresponding per protocol eradication rates were 76.9% and 88.8% for TT and ST, respectively (p=0.000). There were no statistically significant differences between the two regimens with respect to drug compliance and adverse events. Conclusions: ST achieved better eradication rates than TT as a first-line therapy for H. pylori eradication in Korea.
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.